MXC: $0.036
Who

An EU pharmaceutical licensed company, MGC Pharmaceuticals Ltd (ASX: MXC),(MGCLF: OTC US)  is driven by the goal to make Phytomedicines available in pharmacies and to patients in need, in the most cost-effective, consistent and efficient manner possible. 

With many years of real-world, technical and professional experience, MGC Pharma’s founders are all celebrated trailblazers in the Phytocannabinoid industry. MGC Pharma’s main objective is to create and supply superb Cannabinoid based pharmaceutical products for medical markets in North America, Europe, and Australasia.

Read More Read Edison Research On MGC
What

MGC Pharma creates premium phytocannabinoid-based pharmaceutical products from our GMP certified facility in Europe that can be used to treat patients suffering from a variety of symptomatic conditions.

Using a unique labeling system across the range, MGC Pharma has made it simple to understand exactly what Genetic Materials are being utilized in each product. Within the range, each pharmaceutical solution offers a unique combination of cannabinoids in order to address different medical needs. You can learn about the benefits of each of the products below.

Read More
Where

Understanding that we work in an evolving industry which resonates worldwide, MGC Pharmaceuticals places high importance on global activities and supply chain. Unified supply and ability to function dynamically are essential. It permits our IP and experience to enable entry into new markets, helps with the growth of innovation investigation and research institutions (from the government to commercial to educational) and guarantees our products will seamlessly and reliably reach patients and customers, with the strictest QC and QA.

Read More
Why

We’re devoted to providing you with the latest company information. This comprises of ASX announcements, financial reports, and other significant updates. You can also access FAQs and see the latest share price information here. MGC Pharmaceuticals trades on the Australian Securities Exchange (ASX) under the ticker code MXC.

Read More
Why Invest
Latest News
4/3/19Edison Report 1/3/19Interim Financial Report 1/2/19MXC Botanical Update 29/1/19Completion of MGC Derma Sale to CannaGlobal
Read More News
Why Phytocannabinoid-based medicines
Publications

Download our publications on Medicinal Cannabis in Australia, Science, Regulation and the industry as a whole. Developed in partnership with prestigious universities, academia and pioneers in the industry, our publications set out the key challenges, risks and opportunities associated with establishing a national Medicinal Cannabis scheme in Australia.

10/8/16Clinical Evidence for Medicinal Cannabis Report 21/3/16Medicinal Cannabis in Australia, Science, Regulation & Industry
Read More Publications
Latest MGC Annual Report
Investor Information

Sign up to MGC Pharma’s Investor Information to receive the latest news, updates, announcements and investor presentations, straight to your inbox.


MGC Pharmaceuticals partners and collaborates with academia, worldwide prominent universities and companies all over the world to conduct extensive research and develop the highest quality products for our patients.

Research and Educational Partners

Distribution Partners

Clients

View all our partners
ASX: MXC
$0.036
Sunday, 24 March 2019
Latest Announcements
13/3/19Initial Director's Interest Notice Appx 3X Dr Stephen Parker 13/3/19European Corporate and Pharma Industry Expert Appointed NED 28/2/19Half Yearly Report and Accounts 28/2/19Resignation of Joint Company Secretary 26/2/19Independent Validation of MXC High-Grade Cannabis Genetics 25/2/19Change of Director's Interest Notice- Appx 3Y Roby Zomer 25/2/19Change of Director's Interest Notice- Appx 3Y Nativ Segev
Subscribe for news

Australia
Pharma Corporate & Financial Headquarters
Slovenia
Pharma European Operational Headquarters
Malta
Czech Republic
Botanical Research and Development Project
UK
European Corporate Headquarters
Israel
Pharma Scientific Board
Who
What
Where
Why